A journal club meeting focuses on the critical appraisal of recent clinical studies and promotional materials. Participants are tasked with identifying the core methodological flaws, statistical misrepresentations, or biases inherent in various texts. Match each of the following literature excerpts (left) with its corresponding epidemiological concept or limitation (right).
- The efficacy analysis of a new biologic therapy excluded participants who required rescue corticosteroids during the 52-week trial, evaluating only those who strictly maintained their assigned monotherapy.Violation of intention-to-treat principles, increasing susceptibility to attrition bias
- A promotional brochure for a direct oral anticoagulant prominently features a 50% decrease in recurrent deep vein thrombosis, derived from an incidence reduction from 2.0% to 1.0%.Misleading emphasis on relative risk reduction over absolute risk reduction
- A phase III trial for a novel oncology drug establishes efficacy by demonstrating a statistically significant improvement in progression-free survival, which is subsequently used to market the drug for improving overall survival.Extrapolation of clinical benefit from an unvalidated surrogate endpoint
- A retrospective cohort study reports that patients prescribed a new bronchodilator have a higher rate of severe asthma exacerbations than those on older therapies, without adjusting for baseline disease severity.Confounding by indication (channeling bias)
Cevap
Excerpt 1 pairs with Violation of intention-to-treat principles; Excerpt 2 pairs with Misleading emphasis on relative risk reduction; Excerpt 3 pairs with Extrapolation of clinical benefit from surrogate endpoint; Excerpt 4 pairs with Confounding by indication.
In medical literature interpretation, physicians must identify methodological flaws that compromise study validity. Excluding protocol violators (Excerpt 1) creates a per-protocol analysis, disrupting randomization and introducing attrition bias. Pharmaceutical advertisements often highlight relative risk reduction (Excerpt 2) to magnify small absolute benefits. Using surrogate endpoints like progression-free survival (Excerpt 3) does not guarantee improvement in true clinical endpoints like overall survival. Finally, unadjusted observational studies of drug efficacy (Excerpt 4) are highly susceptible to confounding by indication, as sicker patients are more likely to receive newer or more aggressive treatments.
Adım Adım Çözüm
Anahtar Kavram
Critical evaluation of clinical trial design, bias, and pharmaceutical marketing claims